RT Journal Article
T1 Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.
A1 Sampath, Vanitha
A1 Rabinowitz, Grace
A1 Shah, Mihir
A1 Jain, Surabhi
A1 Diamant, Zuzana
A1 Jesenak, Milos
A1 Rabin, Ronald
A1 Vieths, Stefan
A1 Agache, Ioana
A1 Akdis, Mübeccel
A1 Barber, Domingo
A1 Breiteneder, Heimo
A1 Chinthrajah, Sharon
A1 Chivato, Tomas
A1 Collins, William
A1 Eiwegger, Thomas
A1 Fast, Katharine
A1 Fokkens, Wytske
A1 O'Hehir, Robyn E
A1 Ollert, Markus
A1 O'Mahony, Liam
A1 Palomares, Oscar
A1 Pfaar, Oliver
A1 Riggioni, Carmen
A1 Shamji, Mohamed H
A1 Sokolowska, Milena
A1 Jose Torres, Maria
A1 Traidl-Hoffmann, Claudia
A1 van Zelm, Menno
A1 Wang, De Yun
A1 Zhang, Luo
A1 Akdis, Cezmi A
A1 Nadeau, Kari C
K1 COVID-19
K1 SARS-CoV-2
K1 allergy
K1 anaphylaxis
K1 vaccine
AB Vaccines are essential public health tools with a favorable safety profile and prophylactic effectiveness that have historically played significant roles in reducing infectious disease burden in populations, when the majority of individuals are vaccinated. The COVID-19 vaccines are expected to have similar positive impacts on health across the globe. While serious allergic reactions to vaccines are rare, their underlying mechanisms and implications for clinical management should be considered to provide individuals with the safest care possible. In this review, we provide an overview of different types of allergic adverse reactions that can potentially occur after vaccination and individual vaccine components capable of causing the allergic adverse reactions. We present the incidence of allergic adverse reactions during clinical studies and through post-authorization and post-marketing surveillance and provide plausible causes of these reactions based on potential allergenic components present in several common vaccines. Additionally, we review implications for individual diagnosis and management and vaccine manufacturing overall. Finally, we suggest areas for future research.
YR 2021
FD 2021-06-04
LK http://hdl.handle.net/10668/17526
UL http://hdl.handle.net/10668/17526
LA en
DS RISalud
RD Apr 7, 2025